DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report

• Published in: Polish journal of radiology 2018-05, Vol.83, p.e220-228
• Main Authors: Sharma, Anjna, Sharma, Sanjiv, Sood, Shikha, Seam, Rajeev K, Sharma, Mukesh, Fotedar, Vikas
• Format: Article
• Language: English
• Subjects: Original Paper
• ISSN: 1733-134X; 1899-0967; 1899-0967
• DOI: 10.5114/pjr.2018.76271

Neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables evaluation of the tumour neovasculature that occurs prior to any volume change, which helps identify early treatment failures and allows prompt implementation of second-line therapy. We conducted a prospective study in 14 patients with histopathologically proven breast cancer. DCE-MRI data were acquired using multisection, T1-weighted, 3D vibe sequences with fat suppression before, during, and after IV bolus injection (0.1 mmol/kg body weight, Gadoversetamide, Optimark). Post-processing of dynamic contrast perfusion data was done with the vendor's Tissue 4D software to generate various dynamic contrast parameters, i.e. Ktrans, Kep, Ve, initial area under the time signal curve (IAUC), apparent diffusion coefficient (ADC), and enhancement curve. Patients underwent MRI examinations at baseline, and then after two cycles, and finally at completion of chemotherapy. Based on Sataloff criteria for pathological responses, four patients out of 14 were responders, and 10 were non-responders. At the 2nd MRI examination, IAUC was significantly smaller in responders than in non-responders ( = 0.023). When the results of the first and second MRI examinations were compared, Kep decreased from baseline to the second MRI ( = 0.03) in non-responders and in responders ( = 0.04). This change was statistically significant in both groups. The ADC values increased significantly in responders from baseline to the third MRI ( = 0.012). In our study, IAUC and ADC were the only parameters that reliably differentiated responders from non-responders after two and three cycles of chemotherapy.